

# Markus Mschen

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5298370/markus-muschen-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

177  
papers

4,001  
citations

38  
h-index

61  
g-index

181  
ext. papers

5,119  
ext. citations

9.6  
avg, IF

5.05  
L-index

#	Paper	IF	Citations
177	CCND3 is indispensable for the maintenance of B-cell acute lymphoblastic leukemia.. <i>Oncogenesis</i> , <b>2022</b> , 11, 1	6.6	
176	An instructive role for Interleukin-7 receptor in the development of human B-cell precursor leukemia.. <i>Nature Communications</i> , <b>2022</b> , 13, 659	17.4	3
175	SYK and ZAP70 kinases in autoimmunity and lymphoid malignancies.. <i>Cellular Signalling</i> , <b>2022</b> , 110331	4.9	0
174	Beta-Catenin Forms Repressive Complexes with Ikzf1 and Ikzf3 to Orchestrate Tumor-Suppression in B-Cell Malignancies. <i>Blood</i> , <b>2021</b> , 138, 29-29	2.2	
173	Leveraging Pathway-Interference to Overcome Drug-Resistance in Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2021</b> , 138, 616-616	2.2	1
172	Identification of a Conserved Intracellular Loop (CIL) Structure That Scaffolds PIP3 to Amplify Oncogenic Signaling during Malignant B-Cell Transformation. <i>Blood</i> , <b>2021</b> , 138, 868-868	2.2	
171	Identification of BCL6 As Synthetic Lethality in RAS-Driven B-Cell Transformation. <i>Blood</i> , <b>2021</b> , 138, 792-792		
170	Deciphering intratumoral heterogeneity using integrated clonal tracking and single-cell transcriptome analyses. <i>Nature Communications</i> , <b>2021</b> , 12, 6522	17.4	2
169	Structural Basis of Feedback Control of Oncogenic Signaling in B-Lymphoid Malignancies. <i>Blood</i> , <b>2021</b> , 138, 355-355	2.2	
168	R-2-hydroxyglutarate attenuates aerobic glycolysis in leukemia by targeting the FTO/mA/PFKP/LDHB axis. <i>Molecular Cell</i> , <b>2021</b> , 81, 922-939.e9	17.6	46
167	Topography of transcriptionally active chromatin in glioblastoma. <i>Science Advances</i> , <b>2021</b> , 7,	14.3	4
166	Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer. <i>Molecular Cell</i> , <b>2021</b> , 81, 2094-2111.e9	17.6	5
165	Metabolic determinants of B-cell selection. <i>Biochemical Society Transactions</i> , <b>2021</b> , 49, 1467-1478	5.1	
164	Targeted PI3K/AKT-hyperactivation induces cell death in chronic lymphocytic leukemia. <i>Nature Communications</i> , <b>2021</b> , 12, 3526	17.4	9
163	Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2021</b> , 20, 1820-1835	6.1	1
162	Metabolic Gatekeepers of Pathological B Cell Activation. <i>Annual Review of Pathology: Mechanisms of Disease</i> , <b>2021</b> , 16, 323-349	34	4
161	PON2 subverts metabolic gatekeeper functions in B cells to promote leukemogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2021</b> , 118,	11.5	3

160	High-resolution characterization of gene function using single-cell CRISPR tiling screen. <i>Nature Communications</i> , <b>2021</b> , 12, 4063	17.4	5
159	TNK1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth. <i>Nature Communications</i> , <b>2021</b> , 12, 5337	17.4	1
158	IFITM3 functions as a PIP3 scaffold to amplify PI3K signalling in B cells. <i>Nature</i> , <b>2020</b> , 588, 491-497	50.4	19
157	Coactivation of NF- $\kappa$ B and Notch signaling is sufficient to induce B-cell transformation and enables B-myeloid conversion. <i>Blood</i> , <b>2020</b> , 135, 108-120	2.2	8
156	Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. <i>Cancer Cell</i> , <b>2020</b> , 38, 79-96.e11	24.3	145
155	Synergism between IL7R and CXCR4 drives BCR-ABL induced transformation in Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Nature Communications</i> , <b>2020</b> , 11, 3194	17.4	9
154	Integrin $\beta$ mediates the drug resistance of acute lymphoblastic B-cell leukemia. <i>Blood</i> , <b>2020</b> , 136, 210-223.2	2.2	14
153	IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia. <i>Blood</i> , <b>2020</b> , 136, 1520-1534	2.2	13
152	Signalling input from divergent pathways subverts B cell transformation. <i>Nature</i> , <b>2020</b> , 583, 845-851	50.4	16
151	Fusions Drive Oncogenic Pre-BCR Signaling in B-ALL. <i>Blood Cancer Discovery</i> , <b>2020</b> , 1, 18-20	7	0
150	Core transcriptional regulatory circuitries in cancer. <i>Oncogene</i> , <b>2020</b> , 39, 6633-6646	9.2	15
149	CRISPR/Cas9-mediated gene deletion efficiently retards the progression of Philadelphia-positive acute lymphoblastic leukemia in a p210 BCR-ABL1 mutation mouse model. <i>Haematologica</i> , <b>2020</b> , 105, e232-e236	6.6	2
148	CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies. <i>Science Translational Medicine</i> , <b>2019</b> , 11,	17.5	37
147	Chemical choreography of germinal center B-cell migration. <i>Cell Research</i> , <b>2019</b> , 29, 514-515	24.7	
146	Metabolic gatekeepers to safeguard against autoimmunity and oncogenic B cell transformation. <i>Nature Reviews Immunology</i> , <b>2019</b> , 19, 337-348	36.5	19
145	Histone H3 trimethylation at lysine 36 guides mA RNA modification co-transcriptionally. <i>Nature</i> , <b>2019</b> , 567, 414-419	50.4	232
144	Rationale for targeting BCL6 in -rearranged acute lymphoblastic leukemia. <i>Genes and Development</i> , <b>2019</b> , 33, 1265-1279	12.6	8
143	Targeting PRMT1-mediated FLT3 methylation disrupts maintenance of MLL-rearranged acute lymphoblastic leukemia. <i>Blood</i> , <b>2019</b> , 134, 1257-1268	2.2	11

142	Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-Signaling. <i>Blood</i> , <b>2019</b> , 134, 393-393	2.2	
141	Targeting Unique Synthetic Lethal Interactions between PI3K and MYC in B-ALL. <i>Blood</i> , <b>2019</b> , 134, 3785-3785		
140	Signaling Input from Divergent Pathways Subverts Malignant B-Cell Transformation. <i>Blood</i> , <b>2019</b> , 134, 3944-3944	2.2	
139	Co-Expression of SYK and ZAP70 Subverts Negative B-Cell Selection and Enables Oncogenic Signaling in Multiple B-Cell Malignancies. <i>Blood</i> , <b>2019</b> , 134, 295-295	2.2	
138	Autonomous Ca <sup>2+</sup> Oscillations Reflect Oncogenic Signaling in B-ALL Cells. <i>Blood</i> , <b>2019</b> , 134, 1253-1253	2.2	
137	Ifitm3 Is Essential for PI(3,4,5)P3-Dependent B-Cell Activation and Leukemogenesis. <i>Blood</i> , <b>2019</b> , 134, 2782-2782	2.2	1
136	Identification of ZNF217 As an Essential Oncogenic Gene in B-Cell Acute Lymphoblastic Leukemia By CRISPR/Cas9-Based Library Screening. <i>Blood</i> , <b>2019</b> , 134, 1465-1465	2.2	
135	Rationale for Targeting BCL6 in MLL-Rearranged B-ALL. <i>Blood</i> , <b>2019</b> , 134, 1239-1239	2.2	
134	Paraoxonase 2 Enables Initiation of B-ALL By Subverting Metabolic Gatekeeper Functions. <i>Blood</i> , <b>2019</b> , 134, 746-746	2.2	1
133	Lgr5 Functions As a Critical Negative Regulator of Wnt/ $\beta$ Catenin Signaling and Is Essential for B-Lymphopoiesis and Malignant B-Cell Transformation. <i>Blood</i> , <b>2019</b> , 134, 748-748	2.2	
132	Infectious stimuli promote malignant B-cell acute lymphoblastic leukemia in the absence of AID. <i>Nature Communications</i> , <b>2019</b> , 10, 5563	17.4	12
131	Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma. <i>Blood</i> , <b>2019</b> , 133, 306-318	2.2	16
130	Highly multiplexed and quantitative cell-surface protein profiling using genetically barcoded antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2018</b> , 115, 2836-2841	11.5	30
129	Loss of Pax5 Exploits Sca1-BCR-ABL Susceptibility to Confer the Metabolic Shift Essential for pB-ALL. <i>Cancer Research</i> , <b>2018</b> , 78, 2669-2679	10.1	24
128	Autoimmunity checkpoints as therapeutic targets in B cell malignancies. <i>Nature Reviews Cancer</i> , <b>2018</b> , 18, 103-116	31.3	29
127	B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies. <i>Cell</i> , <b>2018</b> , 173, 470-484.e18	56.2	62
126	CAMKs support development of acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , <b>2018</b> , 11, 30	22.4	13
125	Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells. <i>Cell Reports</i> , <b>2018</b> , 23, 3127-3136	10.6	44

124	Cooperation between SYK and ZAP70 Kinases As a Driver of Oncogenic BCR-Signaling in B-Cell Malignancies. <i>Blood</i> , <b>2018</b> , 132, 3922-3922	2.2	1
123	Lgr5 Enables Positive B-Cell Selection and Tumor-Initiation in B-Cell Malignancies. <i>Blood</i> , <b>2018</b> , 132, 547-547	2.2	2
122	Divergent Evolutionary Trajectories of Erk- and Stat5-Activating Lesions in Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2018</b> , 132, 568-568	2.2	
121	IFITM3-Mediated Regulation of Cell Membrane Dynamics Is Essential for Malignant B-Cell Transformation. <i>Blood</i> , <b>2018</b> , 132, 552-552	2.2	1
120	Novel BAFF-R CAR T-Cell Therapy for CD19 Antigen-Loss Relapsed B Cell Tumors. <i>Blood</i> , <b>2018</b> , 132, 1411-1411	2.2	1
119	Autoimmunity Checkpoints As Therapeutic Targets in B-Cell Malignancies. <i>Blood</i> , <b>2018</b> , 132, 1587-1587	2.2	
118	Pre-BCR Surrogate Light Chain Components VPREB1 and IGLL1 Function As Pre-BCR-Independent Tumor Suppressors in Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2018</b> , 132, 570-570	2.2	
117	Portending death in germinal centers - when B cells know their time is up. <i>Cell Research</i> , <b>2018</b> , 28, 5-6	24.7	1
116	Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures. <i>Molecular Systems Biology</i> , <b>2017</b> , 13, 914	12.2	44
115	Genetic analysis of Ikaros target genes and tumor suppressor function in BCR-ABL1 pre-B ALL. <i>Journal of Experimental Medicine</i> , <b>2017</b> , 214, 793-814	16.6	21
114	Metabolic gatekeeper function of B-lymphoid transcription factors. <i>Nature</i> , <b>2017</b> , 542, 479-483	50.4	119
113	Lineage-Specific Genes Are Prominent DNA Damage Hotspots during Leukemic Transformation of B Cell Precursors. <i>Cell Reports</i> , <b>2017</b> , 18, 1687-1698	10.6	10
112	Infection Exposure Promotes Precursor B-cell Leukemia via Impaired H3K4 Demethylases. <i>Cancer Research</i> , <b>2017</b> , 77, 4365-4377	10.1	43
111	mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph and Ph-like B-ALL. <i>Molecular Cancer Therapeutics</i> , <b>2017</b> , 16, 1942-1953	6.1	6
110	Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival. <i>Nature Immunology</i> , <b>2017</b> , 18, 694-704	19.1	45
109	BCL6 promotes glioma and serves as a therapeutic target. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, 3981-3986	11.5	38
108	Ibrutinib inhibits pre-BCR B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK. <i>Blood</i> , <b>2017</b> , 129, 1155-1165	2.2	47
107	Extrafollicular CD4 T-B interactions are sufficient for inducing autoimmune-like chronic graft-versus-host disease. <i>Nature Communications</i> , <b>2017</b> , 8, 978	17.4	35

106	Valosin-Containing Protein/p97 as a Novel Therapeutic Target in Acute Lymphoblastic Leukemia. <i>Neoplasia</i> , <b>2017</b> , 19, 750-761	6.4	14
105	Circadian clock cryptochrome proteins regulate autoimmunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, 12548-12553	11.5	43
104	B-cell identity as a metabolic barrier against malignant transformation. <i>Experimental Hematology</i> , <b>2017</b> , 53, 1-6	3.1	10
103	Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells. <i>Journal of Clinical Investigation</i> , <b>2017</b> , 127, 2392-2406	15.9	49
102	Autoimmunity Checkpoints As Therapeutic Targets in B- and T-Cell Malignancies. <i>Blood</i> , <b>2017</b> , 130, 718-718		
101	PON2 Exemplifies a Unique Dependency of B Cell Lineage ALL Cells on Detoxifying Lactonases. <i>Blood</i> , <b>2017</b> , 130, 882-882	2.2	
100	PTEN opposes negative selection and enables oncogenic transformation of pre-B cells. <i>Nature Medicine</i> , <b>2016</b> , 22, 379-87	50.5	74
99	mTOR Kinase Inhibitors Enhance Efficacy of TKIs in Preclinical Models of Ph-like B-ALL. <i>Blood</i> , <b>2016</b> , 128, 2763-2763	2.2	4
98	CD25 Enables Oncogenic BCR Signaling and Represents a Therapeutic Target in Refractory B Cell Malignancies. <i>Blood</i> , <b>2016</b> , 128, 4088-4088	2.2	2
97	Inhibition of IRE1 $\beta$ -driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia. <i>Oncotarget</i> , <b>2016</b> , 7, 18736-49	3.3	60
96	Feedback Regulation of STAT5 Is Critical to Balance MYC and BCL6-Dependent Transcriptional Programs That Regulate Cell Size and Glucose Metabolism. <i>Blood</i> , <b>2016</b> , 128, 4069-4069	2.2	0
95	IFITM3 Is a Central Regulator of Lipid Raft Signaling and Essential for CD19 Surface Expression and PI3K Signaling in Human B Cell Malignancies. <i>Blood</i> , <b>2016</b> , 128, 2738-2738	2.2	
94	Transcriptional Regulatory Landscape of TCF3-PBX1-Positive Leukemia and Novel Targeted Treatments. <i>Blood</i> , <b>2016</b> , 128, 4077-4077	2.2	
93	Identification of the Energy Stress Sensor AMPK As Therapeutic Target in Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2016</b> , 128, 2771-2771	2.2	
92	Transcriptional Control of Glucose and Energy Supply Prevents Oncogenic Signaling and B Cell Transformation. <i>Blood</i> , <b>2016</b> , 128, 437-437	2.2	
91	PP2A Balances Glucose Metabolism and Foxo Activation to Maintain Cellular Redox Homeostasis in Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2016</b> , 128, 1056-1056	2.2	1
90	Oncogenic Feedback Activation Between BCL6 and MLL Promotes Malignant Transformation in MLL-Rearranged Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2016</b> , 128, 907-907	2.2	
89	BCL6 Is Critical to Overcome Oncogene-Induced Senescence in RAS-Mediated B Cell Transformation. <i>Blood</i> , <b>2016</b> , 128, 438-438	2.2	

88	Effects of pharmacological and genetic disruption of CXCR4 chemokine receptor function in B-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , <b>2016</b> , 174, 425-36	4.5	21
87	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. <i>Cancer Cell</i> , <b>2016</b> , 29, 574-586	24.3	154
86	Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases. <i>Blood</i> , <b>2016</b> , 127, 2131-43	2.2	18
85	Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia. <i>Cancer Cell</i> , <b>2015</b> , 27, 409-25	24.3	81
84	Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , <b>2015</b> , 28, 114-28	24.3	78
83	Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia. <i>Blood</i> , <b>2015</b> , 125, 3688-93	2.2	28
82	Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. <i>Nature</i> , <b>2015</b> , 521, 357-61	50.4	90
81	YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway. <i>Journal of Hematology and Oncology</i> , <b>2015</b> , 8, 39	22.4	25
80	Identification of FOXM1 as a therapeutic target in B-cell lineage acute lymphoblastic leukaemia. <i>Nature Communications</i> , <b>2015</b> , 6, 6471	17.4	31
79	Human lymphoid translocation fragile zones are hypomethylated and have accessible chromatin. <i>Molecular and Cellular Biology</i> , <b>2015</b> , 35, 1209-22	4.8	6
78	Mechanisms of pre-B-cell receptor checkpoint control and its oncogenic subversion in acute lymphoblastic leukemia. <i>Immunological Reviews</i> , <b>2015</b> , 263, 192-209	11.3	27
77	MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia. <i>Blood</i> , <b>2015</b> , 126, 2202-12	2.2	75
76	Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia. <i>Blood</i> , <b>2015</b> , 126, 1813-22	2.2	65
75	Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia. <i>Nature Immunology</i> , <b>2015</b> , 16, 766-774	19.1	121
74	Infection and the Perils of B-cell Activation. <i>Cancer Discovery</i> , <b>2015</b> , 5, 1244-6	24.4	5
73	MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. <i>Cell Reports</i> , <b>2015</b> , 13, 2715-27	10.6	84
72	Circadian Clock Protein CRY Controls B-Cell Intrinsic Tolerance. <i>Blood</i> , <b>2015</b> , 126, 1029-1029	2.2	1
71	IFITM3 (CD225) Links the B Cell Antigen CD19 to PI3K-AKT Signaling in Human ALL Cells. <i>Blood</i> , <b>2015</b> , 126, 1325-1325	2.2	2



70	CD25 (IL2RA) Orchestrates Negative Feedback Control and Stabilizes Oncogenic Signaling Strength in Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2015</b> , 126, 1434-1434	2.2	3
69	Overcoming Drug Resistance of Pre-B ALL Cells By Targeting Integrin alpha6 Associated Cell-Adhesion Mediated Drug Resistance Using a Novel Antibody, P5G10. <i>Blood</i> , <b>2015</b> , 126, 2525-2525	2.2	1
68	Combined Targeting of JAK2 with a Type II JAK2 Inhibitor and mTOR with a TOR Kinase Inhibitor Constitutes Synthetic Activity in JAK2-Driven Ph-like Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2015</b> , 126, 2529-2529	2.2	3
67	Exposure to Inflammatory Immune Responses As Driver of Clonal Evolution in Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2015</b> , 126, 166-166	2.2	
66	Targeting of Quiescent and Proliferating CML Stem Cells By DNA Repair Inhibitors. <i>Blood</i> , <b>2015</b> , 126, 50-50	2.2	
65	B-Lymphoid Transcription Factors Restrict Glycolytic Energy Supply for Oncogenic Signaling. <i>Blood</i> , <b>2015</b> , 126, 1255-1255	2.2	
64	Targeted Activation of B Cell Autoimmunity Checkpoints in Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2015</b> , 126, 3716-3716	2.2	
63	Extrafollicular CD4+ T and B Interaction Induces Chronic Gvhd in the Absence of Germinal Center Formation. <i>Blood</i> , <b>2015</b> , 126, 1875-1875	2.2	
62	Identification of BCL6 As a Therapeutic Target in RAS-Driven Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2015</b> , 126, 556-556	2.2	
61	PP2A Is Required for B Cell Survival and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2015</b> , 126, 902-902	2.2	
60	Identification and characterization of OSTL (RNF217) encoding a RING-IBR-RING protein adjacent to a translocation breakpoint involving ETV6 in childhood ALL. <i>Scientific Reports</i> , <b>2014</b> , 4, 6565	4.9	11
59	BACH2-BCL6 balance regulates selection at the pre-B cell receptor checkpoint. <i>Trends in Immunology</i> , <b>2014</b> , 35, 131-7	14.4	25
58	RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. <i>Nature Genetics</i> , <b>2014</b> , 46, 116-25	36.3	244
57	Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, E2219-28	11.5	64
56	Targeting the B-cell receptor signaling pathway in B lymphoid malignancies. <i>Current Opinion in Hematology</i> , <b>2014</b> , 21, 341-9	3.3	26
55	BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint. <i>Nature Medicine</i> , <b>2013</b> , 19, 1014-22	50.5	82
54	Bruton's Tyrosine Kinase Inhibitor Ibrutinib Interferes With Constitutive and Induced Pre-B Cell Receptor Signaling In B-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2013</b> , 122, 1399-1399	2.2	2
53	BCL-2-Selective BH3 Mimetic ABT-199 Is a Potent Agent For Acute Myeloid Leukemia. <i>Blood</i> , <b>2013</b> , 122, 1456-1456	2.2	2



52	Ifitm3 (CD225) Mediates CD19-Dependent Survival and Proliferation During Normal B Cell Development and In Ph+ ALL. <i>Blood</i> , <b>2013</b> , 122, 2505-2505	2.2	4
51	Gas7 Induces The Proliferation Of Ph+ ALL Cells and Prevents The Differentiation Of Early B Cell Progenitors Into CD25high Small Pre-B Cells. <i>Blood</i> , <b>2013</b> , 122, 2506-2506	2.2	1
50	Acute Lymphoblastic Leukemia Is a Bcl-2 Dependent Disease: Proteomic Profiling and Pre-Clinical Efficacy Of a Selective Bcl-2 Antagonist ABT-199. <i>Blood</i> , <b>2013</b> , 122, 3919-3919	2.2	1
49	Oncogene-Induced DNA Repair Defects Promote PARP1-Mediated Dual Synthetic Lethality To Eradicate Quiescent and Proliferating Leukemia Stem and Progenitor Cells. <i>Blood</i> , <b>2013</b> , 122, 810-810	2.2	2
48	Targeting Pre-B Cell Receptor and BCL6 In TCF3-PBX1 B-Lineage Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2013</b> , 122, 349-349	2.2	
47	Inhibitory Receptors and Phosphatases Enable Oncogenic Tyrosine Kinase Signaling In B Cell Lineage Leukemia. <i>Blood</i> , <b>2013</b> , 122, 229-229	2.2	
46	Normal ABL1 Is a Tumor Suppressor and Therapeutic Target In BCR-ABL1 Positive Leukemias. <i>Blood</i> , <b>2013</b> , 122, 1466-1466	2.2	
45	Identification Of FOXM1 As Therapeutic Target In BCR-ABL1 Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2013</b> , 122, 1250-1250	2.2	
44	The Plasma Cell Transcription Factor XBP1 is Required To Mitigate The Unfolded Protein Response In Ph+ ALL. <i>Blood</i> , <b>2013</b> , 122, 836-836	2.2	
43	Identification Of BCL6 As a Therapeutic Target In MLL-Rearranged ALL. <i>Blood</i> , <b>2013</b> , 122, 72-72	2.2	
42	Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. <i>Cancer Discovery</i> , <b>2012</b> , 2, 1004-23	24.4	70
41	Targeting the UPR-Transcription Factor XBP1 to Overcome Drug-Resistance in Ph+ ALL. <i>Blood</i> , <b>2012</b> , 120, 872-872	2.2	1
40	SOX4 enables Oncogenic Survival Signals in Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2012</b> , 120, 863-863	2.2	
39	BACH2 Is Required for Pre-B Cell Receptor Checkpoint Control and p53-Dependent Tumor Surveillance. <i>Blood</i> , <b>2012</b> , 120, 1300-1300	2.2	
38	Suppressor of Cytokine Signaling (SOCS) Molecules Are Critical to Balance Oncogenic Signaling Strength in Ph+ ALL. <i>Blood</i> , <b>2012</b> , 120, 2563-2563	2.2	
37	Targeting BCL6-Mediated Drug-Resistance in High-Risk Childhood ALL. <i>Blood</i> , <b>2012</b> , 120, 776-776	2.2	
36	Negative Feedback Signaling Enables Leukemic Transformation by Oncogenic Tyrosine Kinases. <i>Blood</i> , <b>2012</b> , 120, 1352-1352	2.2	
35	BCL6 Interacting Corepressor (BCOR) Functions As Lineage-Specific Tumor Suppressor in B Lymphoid and Myeloid Leukemia. <i>Blood</i> , <b>2012</b> , 120, 1301-1301	2.2	

34	ITIM-Containing Inhibitory Receptors Are Required to Balance Oncogenic Signaling Strength in Ph+ ALL. <i>Blood</i> , <b>2012</b> , 120, 291-291	2.2	
33	BCOR Is Involved in Myeloid Cell Growth Control by Regulating Hox Genes. <i>Blood</i> , <b>2012</b> , 120, 3445-3445	2.2	1
32	Lineage-Specific Functions of LKB1 in CML and B Lymphoid Blast Crisis. <i>Blood</i> , <b>2012</b> , 120, 34-34	2.2	
31	Functional Modulation of VLA6 in BCR-ABL1+ Pre-B Acute Lymphoblastic Leukemia.. <i>Blood</i> , <b>2012</b> , 120, 2565-2565	2.2	
30	Identification of FoxM1 As Therapeutic Target in TKI-Resistant Ph+ ALL. <i>Blood</i> , <b>2012</b> , 120, 874-874	2.2	
29	Integrative Analysis of Ikaros-Dependent Changes of Transcriptional Regulation and Tyrosine Phosphorylation Events in Ph+ ALL. <i>Blood</i> , <b>2012</b> , 120, 528-528	2.2	
28	Cooperation Between Aid and the Rag1/Rag2 V(D)J Recombinase Drives Clonal Evolution of Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2012</b> , 120, 519-519	2.2	
27	Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia. <i>Blood</i> , <b>2011</b> , 118, 2191-9	2.2	89
26	BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. <i>Nature</i> , <b>2011</b> , 473, 384-8	50.4	154
25	Global phosphoproteomics reveals crosstalk between Bcr-Abl and negative feedback mechanisms controlling Src signaling. <i>Science Signaling</i> , <b>2011</b> , 4, ra18	8.8	52
24	DUSP6-Mediated Negative Feedback to Oncogenic Tyrosine Kinase Signaling Prevents Excessive Accumulation of ROS and Enables Leukemia Cell Survival. <i>Blood</i> , <b>2011</b> , 118, 1479-1479	2.2	1
23	BCL6-Mediated Repression of p53 Is Critical for Leukemia Stem Cell Survival in Chronic Myeloid Leukemia. <i>Blood</i> , <b>2011</b> , 118, 446-446	2.2	
22	Targeting Inhibitory Phosphatases in Tyrosine Kinase-Driven Leukemias. <i>Blood</i> , <b>2011</b> , 118, 1382-1382	2.2	
21	Infectious Origins of Childhood Leukemia. <i>Blood</i> , <b>2011</b> , 118, 751-751	2.2	
20	Mechanisms of Ikaros-Mediated Tumor Suppression. <i>Blood</i> , <b>2011</b> , 118, 408-408	2.2	
19	Pre-B Cell Receptor-Mediated Activation of BCL6 Induces Pre-B Cell Quiescence Through Transcriptional Repression of MYC. <i>Blood</i> , <b>2011</b> , 118, 1406-1406	2.2	
18	BACH2 Mediates Early B Cell Differentiation and Oncogene-Induced Senescence in Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2011</b> , 118, 562-562	2.2	
17	Compensatory Signaling From ROR1 and the Pre-B Cell Receptor Promote Survival of t(1;19) Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2011</b> , 118, 2466-2466	2.2	

16	Targeting Survivin with YM155 As a Potential Therapy in Pediatric Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2011</b> , 118, 2490-2490	2.2	
15	BCL6 is critical for the development of a diverse primary B cell repertoire. <i>Journal of Experimental Medicine</i> , <b>2010</b> , 207, 1209-21	16.6	89
14	BCL6 Is Required for the Maintenance of Leukemia-Initiating Cells In Chronic Myeloid Leukemia. <i>Blood</i> , <b>2010</b> , 116, 202-202	2.2	0
13	IKAROS and BCL6 Limit Pre-B Cell Expansion and Prevent Leukemogenesis Downstream of the Pre-B Cell Receptor. <i>Blood</i> , <b>2010</b> , 116, 146-146	2.2	
12	The Tumor Suppressor PTEN Is Required to Prevent Cellular Senescence and Cell Cycle Arrest In B Cell Lineage and Chronic Myeloid Leukemia. <i>Blood</i> , <b>2010</b> , 116, 513-513	2.2	1
11	IL7R $\beta$ Signaling Prevents Premature Expression of AID In Human Pre-B Cells: Implications for Clonal Evolution of Childhood Leukemia. <i>Blood</i> , <b>2010</b> , 116, 26-26	2.2	
10	Pre-B Cell Receptor Signaling Distinguishes E2A-PBX1 From Other Subtypes of Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2010</b> , 116, 274-274	2.2	1
9	SYK Is a Tumor Suppressor In Pre-B Cell Acute Lymphoblastic Leukemia and Not a Therapeutic Target. <i>Blood</i> , <b>2010</b> , 116, 4199-4199	2.2	
8	Mechanisms of Pre-B Cell Receptor-Inactivation In Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2010</b> , 116, 147-147	2.2	
7	Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function. <i>Journal of Experimental Medicine</i> , <b>2009</b> , 206, 1739-53	16.6	108
6	The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia. <i>Cancer Cell</i> , <b>2009</b> , 16, 232-45	24.3	122
5	Human chromosomal translocations at CpG sites and a theoretical basis for their lineage and stage specificity. <i>Cell</i> , <b>2008</b> , 135, 1130-42	56.2	183
4	Conventional light chains inhibit the autonomous signaling capacity of the B cell receptor. <i>Immunity</i> , <b>2007</b> , 26, 323-33	32.3	63
3	Tracing the pre-B to immature B cell transition in human leukemia cells reveals a coordinated sequence of primary and secondary IGK gene rearrangement, IGK deletion, and IGL gene rearrangement. <i>Journal of Immunology</i> , <b>2005</b> , 174, 367-75	5.3	38
2	Mimicry of a constitutively active pre-B cell receptor in acute lymphoblastic leukemia cells. <i>Journal of Experimental Medicine</i> , <b>2005</b> , 201, 1837-52	16.6	61
1	Deficiency of Bruton's tyrosine kinase in B cell precursor leukemia cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2005</b> , 102, 13266-71	11.5	43